260 related articles for article (PubMed ID: 31624127)
41. The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
Spaans VM; Nyoman Bayu Mahendra I; Purwoto G; Trietsch MD; Osse M; Ter Haar N; Peters AAW; Fleuren GJ; Jordanova ES
Gynecol Oncol; 2018 Jan; 148(1):189-196. PubMed ID: 29113722
[TBL] [Abstract][Full Text] [Related]
42. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
[TBL] [Abstract][Full Text] [Related]
43. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
[TBL] [Abstract][Full Text] [Related]
44. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
Wright AA; Howitt BE; Myers AP; Dahlberg SE; Palescandolo E; Van Hummelen P; MacConaill LE; Shoni M; Wagle N; Jones RT; Quick CM; Laury A; Katz IT; Hahn WC; Matulonis UA; Hirsch MS
Cancer; 2013 Nov; 119(21):3776-83. PubMed ID: 24037752
[TBL] [Abstract][Full Text] [Related]
45. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
Cufí S; Corominas-Faja B; Lopez-Bonet E; Bonavia R; Pernas S; López IÁ; Dorca J; Martínez S; López NB; Fernández SD; Cuyàs E; Visa J; Rodríguez-Gallego E; Quirantes-Piné R; Segura-Carretero A; Joven J; Martin-Castillo B; Menendez JA
Oncotarget; 2013 Sep; 4(9):1484-95. PubMed ID: 23986086
[TBL] [Abstract][Full Text] [Related]
46. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
[TBL] [Abstract][Full Text] [Related]
47. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
[TBL] [Abstract][Full Text] [Related]
48. Driver gene mutations in micro-invasive cervical squamous cancers have no prognostic significance.
Kashofer K; Regauer S; Reich O; Petru E; Winter E
Gynecol Oncol; 2022 Apr; 165(1):121-128. PubMed ID: 35101299
[TBL] [Abstract][Full Text] [Related]
49. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
Hou MM; Liu X; Wheler J; Naing A; Hong D; Coleman RL; Tsimberidou A; Janku F; Zinner R; Lu K; Kurzrock R; Fu S
Oncotarget; 2014 Nov; 5(22):11168-79. PubMed ID: 25426553
[TBL] [Abstract][Full Text] [Related]
50. Identification of genetic alterations in extramammary Paget disease using whole exome analysis.
Kiniwa Y; Yasuda J; Saito S; Saito R; Motoike IN; Danjoh I; Kinoshita K; Fuse N; Yamamoto M; Okuyama R
J Dermatol Sci; 2019 Apr; 94(1):229-235. PubMed ID: 31023612
[TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Lachkar B; Minaguchi T; Akiyama A; Liu S; Zhang S; Xu C; Shikama A; Tasaka N; Sakurai M; Nakao S; Ochi H; Yoshikawa H; Satoh T
Medicine (Baltimore); 2018 Aug; 97(31):e11392. PubMed ID: 30075505
[TBL] [Abstract][Full Text] [Related]
52. Multi-region sequencing depicts intratumor heterogeneity and clonal evolution in cervical cancer.
Wang C; Bai R; Liu Y; Wang K; Wang Y; Yang J; Cai H; Yang P
Med Oncol; 2023 Jan; 40(2):78. PubMed ID: 36635412
[TBL] [Abstract][Full Text] [Related]
53. PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [
Magometschnigg H; Pinker K; Helbich T; Brandstetter A; Rudas M; Nakuz T; Baltzer P; Wadsak W; Hacker M; Weber M; Dubsky P; Filipits M
Mol Imaging Biol; 2019 Oct; 21(5):991-1002. PubMed ID: 30652258
[TBL] [Abstract][Full Text] [Related]
54. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
[TBL] [Abstract][Full Text] [Related]
55. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
[TBL] [Abstract][Full Text] [Related]
56. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
McIntyre JB; Wu JS; Craighead PS; Phan T; Köbel M; Lees-Miller SP; Ghatage P; Magliocco AM; Doll CM
Gynecol Oncol; 2013 Mar; 128(3):409-14. PubMed ID: 23266353
[TBL] [Abstract][Full Text] [Related]
57. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
[TBL] [Abstract][Full Text] [Related]
58. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Tornesello ML; Annunziata C; Buonaguro L; Losito S; Greggi S; Buonaguro FM
J Transl Med; 2014 Sep; 12():255. PubMed ID: 25220666
[TBL] [Abstract][Full Text] [Related]
59. Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
Shariati M; Evans KW; Zheng X; Bristow CA; Ng PK; Rizvi YQ; Tapia C; Yang F; Carugo A; Heffernan TP; Peoples MD; Tripathy D; Meric-Bernstam F
Oncogene; 2021 Jul; 40(26):4425-4439. PubMed ID: 34108622
[TBL] [Abstract][Full Text] [Related]
60. High incidence of PI3K pathway gene mutations in South Indian cervical cancers.
Rose MM; Dhamodharan S; Revathidevi S; Chakkarappan SR; Jagadeesan MG; Subbiah S; Nakaoka H; Inoue I; Murugan AK; Munirajan AK
Cancer Genet; 2022 Jun; 264-265():100-108. PubMed ID: 35568000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
